Miravo Healthcare™ Announces Director Election Results of its Annual Meeting of Shareholders

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company) a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced that at its 2022 Virtual Annual Meeting of Shareholders held on May 16, 2022 (the Meeting), all nominees listed in the management proxy circular dated April 8, 2022 were elected as directors of the Company.

The detailed results of the votes by proxy and virtual votes received at the Meeting are as follows:

DIRECTOR NOMINEES	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST
	FOR	WITHHELD	FOR	WITHHELD
Daniel Chicoine	3,229,640	334,343	90.62	9.38
Anthony Dobranowski	3,293,159	270,824	92.40	7.60
Robert Harris	3,319,014	244,969	93.13	6.87
John London	3,112,855	451,128	87.34	12.66
Mary Ritchie	3,364,247	199,736	94.40	5.60
Dale MacCandlish Weil	3,363,540	200,443	94.38	5.62

In addition, the Company reports that the appointment of Ernst & Young LLP as the Company’s auditors for the ensuing fiscal year was passed by a majority of the votes represented at the Meeting. The Company’s full report of voting results on matters presented at the Meeting can be found at www.sedar.com.

About Miravo Healthcare

Miravo is a Canadian-focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company targets several therapeutic areas, including pain, allergy, neurology and dermatology. The Company’s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Miravo’s head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the Company’s manufacturing facility is located in Varennes, Québec, Canada. The Varennes facility operates in a Good Manufacturing Practices (GMP) environment respecting the U.S., Canada and E.U. GMP regulations and is regularly inspected by Health Canada and the U.S. Food and Drug Administration. For additional information, please visit www.miravohealthcare.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220516005748/en/

Investor Relations

Stefan Eftychiou

905 326 1888 ext 60

stefan@bristolir.com

Source: Nuvo Pharmaceuticals Inc.